RegMed Investors’ (RMi) pre-open: investors seek answers or at least a response…

December 11, 2023 7:51am

Will they ever get the full story, it’s not written yet?

News: bluebird bio (BLUE +$0.16 or +5.59% in pre-market) updated data from gene therapy program in transfusion-dependent (TDT) beta-thalassemia; data showed sustained treatment effect, reduced iron management burden and improved quality of life measures in patients with beta-thalassemia who require regular red blood cell transfusions following treatment with betibeglogene autotemcel (beti-cel) (FDA approved and marketed in the U.S. as ZYNTEGLO™). <65th American Society of Hematology (ASH) Annual Meeting & Exposition>

Pre-open Indications: 4 Positive, 2 Negative and 1 Sell into Strength Indications

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

I support Israel, mind body and spirit

Remember that overnight action in a.m. Futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Sentiment seems fleeting. My usual question, are we facing a prisoner’s dilemma - a situation wherein algorithms acting with electronic trading interest do not achieve a continued optimal outcome for this investor group

The pre-open Dow futures are DOWN -0.02% or (-6 points), the S&P is DOWN -0.05% or (-2 points) as the Nasdaq is DOWN -0.13% or (-21 points)

U.S. stock futures are fluctuating to the weak side on Monday,

European markets mixed

Asia Pacific were up and higher.

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed higher Friday as the Dow closed UP +130.49 points or +0.36%, the S&P closed UP +18.78 points or +0.41% while the Nasdaq closed UP +63.98 points or +0.45%

Economic Data Docket: No data on Monday …

Friday, RegMed Investors (RMi) Closing Bell: “good, bad, conflicting news and a negative sector close.  Biotech, healthcare, cell and gene therapy sector are about to be possibly scammed for their patents by current administration.” … https://www.regmedinvestors.com/articles/13239

Q4:  December – 4 positive and 2 negative closes

• November – 11 positives, 1 holiday and 10 negative closes
• October – 1 sick day, 9 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context: looking for lost SHEAP …

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indications:

Friday’s closing price, some Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed up +$0.20 after Thursday’s +$1.36, Wednesday’s -$0.89, Tuesday’s +$0.59 and last Monday’s +$0.70 with a neutral $0.00 or 0% pre-open indication.

Negative Indications:

Friday’s closing price, some Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Solid Biosciences (SLDB) closed down -$0.70 after Thursday’s +$2.34 after receiving Fast Track Designation from the FDA for SGT-003, it’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate following Wednesday’s -$0.33, Tuesday’s +$0.31 and last Monday’s +$0.52 with a negative -$0.01 or -0.20% pre-open indication.

Prime Medicine (PRME) closed down -$0.06 after Thursday’s +$0.17, Wednesday’s +$0.54 and Tuesday’s -$0.22 with a neutral -$0.00 or -0% pre-open indication.

Positive Indications:

Friday’s closing price, some Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$7.22 after Thursday’s +$2.24, Wednesday’s +$4.65, Tuesday’s -$2.50 and Monday’s +$1.36 with a positive +$0.73 or +0.43% pre-open indication.

bluebird bio (BLUE) closed down -$1.95 after Thursday’s -$0.02 and Wednesday’s +$0.50 with a positive +$0.16 or +5.59% pre-open indication.

Intellia Therapeutics (NTLA) closed down -$0.76 after Thursday’s -$0.08 and Wednesday’s -$0.04 with a negative -$0.18 or -0.62% pre-open indication

Ionis Pharmaceuticals (IONS) closed down -$0.78 after Thursday’s -$0.47, Wednesday’s -$0.06, Tuesday’s -$1.46 after Monday’s -$0.17 with a positive +$1.81 or +3.72% pre-open indication.

The BOTTOM LINE:  highs only last so long unless you take another “hit”?

Markets enter the week with serious momentum, as all three major US stock market indexes have finished the last six weeks with gains. <Yahoo Finance>

• For the year, the Dow is up more than 9%, the S&P 500 is up nearly 20% (ess than 5% away from its record closing high) while the Nasdaq gained nearly 38%.

Not changing my “tune” … I remain a skeptic, thus maintaining; investors should consider getting defensive…

• If dead wood or too struggling share pricings are in the portfolio; especially those desperately needing a financing, lacking a partner, restructuring and needing a financing or just wallowing in the market …
• Portfolio rebalancing might also involve taking some profits in some ascending cell and gene therapy equities.
• It’s up to you to decide!

I am STILL waiting for catalysts to justify recent upside appreciation as some news sinks the share pricing other than algorithmic electronic trading!

• I also DON’T believe totally we are finished with economic speedbumps and rate increases in THIS end of year and upcoming 2024 market.
• Being that I have concerns over the resiliency of upside moves that usually end in downward sells as the risk/reward profile doesn’t always compel elevated and “dramatic” i.e., sudden equity pricing.
• While optimism for December remains high, some analysts worry the run-up has been too big, too fast. <The Street>
• Again, it might be prudent to harvest and cash in some chips following the past month’s dramatic rally.

Today’s relevancy from Friday’s session:

• The Dow has been overbought for 12 straight days — even if it is 500 points below its all-time high of about 36,953.
• Inflation is down substantially from the 9.1% it reached in mid-June 2022. The CPI was up 3.2% year-over-year in September and October.
• The 10-year Treasury yield, which exerts a huge influence on mortgage rates, finished the past week at 4.23%, down from a peak of 5.02% in mid-October. The most recent Freddie Mac survey of mortgage rates put the rate on new 30-year mortgages at 7.03%, down from a peak of 7.79% on Oct. 26.
• The Nasdaq Index is nearing a 52-week high.
•  TIME to fly away!!

It's time to think ahead to December. It's usually an important month for the Nasdaq.

• Don’t FORGET portfolio tax selling and a bit of rebalancing
• And then comes January and with worries that the U.S. economy will be slowing down, the potential for continued Middle East violence and, of course, the real prospect of bitterly contested elections across all of the United States. <The Street>

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.